Mitral regurgitation after anthracycline exposure: a case report
Journal Title: OncoReview - Year 2014, Vol 4, Issue 4
Abstract
We report the case of a 66-year-old African American female with a history of breast cancer previously treated with anthracycline based chemotherapy presenting with significant mitral regurgitation. She initially had preserved left ventricular systolic function with normal cardiac chamber dimensions, however, she developed progressive left ventricular chamber dilation and mild reduction in systolic function, which prompted surgical correction of her mitral regurgitation. After surgical mitral valve repair, she developed overt left ventricular failure with severe systolic dysfunction; however, she responded well to subsequent medical therapy
Authors and Affiliations
Gregory Hartlage, Palmer Cole, Aarti Patel, C. Morales, Eric Harrison
Keywords
Related Articles
- EP ID EP67766
- DOI -
- Views 194
- Downloads 0
Hope
In our next article we would like to draw your attention to issue of hope. Taking into account our experience with one of our patient our goal is to establish what hope means for a person in the terminal phase of cancer....
Cardio-oncology: What is the future?
Changes in the gastrointestinal mucosa after radio- and chemotherapy of the neoplasms
Gastrointestinal mucositis induced by radio- and chemotherapy of the neoplasms is associated with morphological changes in the mucosa of the alimentary tract. The pain, ulceration, nausea, vomiting and diarrhea are the e...
Większa skuteczność nilotynibu niż imatynibu w leczeniu przewlekłej białaczki szpikowej w fazie przewlekłej. Analiza aktualnych wyników badania ENESTnd i ENESTcmr
Inhibitory kinaz tyrozynowych II generacji jako pierwszy wybór w przewlekłej białaczce szpikowej (CML) w fazie przewlekłej zwiększają skuteczność terapii i poprawiają rokowanie. Pierwotnym celem badania ENESTnd było poró...
Targeted therapies for chronic myeloid leukemia and cardiovascular system
Morbidity of chronic myeloid leukemia is recorded in elderly population, in patients with coexisting significant risk factors for atherosclerosis and heart diseases. Molecularly targeted therapy, imatinib, dasatinib and...